Medtronic's Hugo Robot Wins FDA Clearance for General Surgery, Doubling Its Addressable Market

The FDA cleared Medtronic's Hugo robot for six abdominal procedures that together account for 3.5 million US surgeries a year, moving the system beyond urology.

Key Takeaways

  • The FDA cleared Medtronic's Hugo robotic-assisted surgery system for six general surgery procedures on November 17, 2026.
  • The newly cleared procedures include cholecystectomy, gastric bypass, hernia repair, bowel resection and appendectomy, covering about 3.5 million US surgeries annually.
  • Hugo was previously cleared only for urology procedures in the United States.
  • Medtronic says Hugo procedure growth is running at more than twice the pace of the broader robotic-surgery market, with over 50,000 procedures expected by fiscal year-end.
  • The clearance puts Medtronic in closer competition with Intuitive Surgical's da Vinci system and J&J's Ottava platform in general surgery.

Medtronic's Hugo Robot Wins FDA Clearance for General Surgery, Doubling Its Addressable Market

Medtronic has won FDA clearance to use its Hugo robotic-assisted surgery system for general surgery, expanding the device beyond the urology indication it launched with in the United States. The company announced the 510(k) clearance on November 17, 2026, covering six procedure types that together account for roughly 3.5 million surgeries a year in the country, more than half of all soft-tissue operations performed annually.

The clearance splits into two groups. Upper abdominal procedures now covered include cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection. Lower abdominal clearances cover inguinal hernia repair and appendectomy. Matt Anderson, senior vice president and president of Medtronic's surgical business, said Hugo "expands choice with a practical option to help hospitals address capacity and access challenges." Dr. Francesco Bianco of UI Health said the broader indication lets his team "offer additional treatment options" to patients.

Why This Matters for Robotic Surgery

Hugo entered the US market through urology, a smaller category long dominated by Intuitive Surgical's da Vinci platform, which has more than two decades of general-surgery clearances already on file. General surgery is a different scale of opportunity: Medtronic says Hugo procedure growth is already running at more than twice the pace of the broader robotic-surgery market and is on track to surpass 50,000 procedures by the end of the company's fiscal year. Adding cholecystectomy and hernia repair, two of the most frequently performed operations in American hospitals, gives Medtronic a far larger addressable pool than urology alone offered.

The move also intensifies competition in a field that has grown crowded. Johnson & Johnson's Ottava system and Virtuoso Surgical's endoluminal platform have both picked up FDA clearances this year, while Intuitive continues to defend its installed base of thousands of da Vinci units worldwide. Medtronic is betting that hospitals already running Hugo for urology will expand usage into general surgery rather than buy a second system, lowering the effective cost per procedure and making the platform more attractive to health systems watching capital budgets.

What Happens Next

Medtronic will now work to get Hugo onto general-surgery schedules at hospitals that already own the system, a process that typically involves surgeon training and credentialing rather than new capital purchases. The company's LigaSure RAS Maryland instrument, already used in more than 45 million open and laparoscopic procedures, is expected to ship alongside Hugo in these new indications, giving surgeons a familiar energy device on an expanded robotic platform. Medtronic has not said when it expects to seek clearance for additional procedure types or international markets beyond the US.

Category: Surgical Robotics

Tags: Surgical Robotics FDA Clearance Hugo RAS Intuitive Surgical Medtronic

Related Articles

Frequently Asked Questions

What procedures can Medtronic's Hugo robot now perform?

Hugo is now cleared for cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair, small bowel resection, inguinal hernia repair and appendectomy, in addition to its existing urology clearance.

When did the FDA clear Hugo for general surgery?

The FDA clearance was announced by Medtronic on November 17, 2026.

How big is the market for these newly cleared procedures?

Medtronic says the six procedure types account for roughly 3.5 million surgeries performed in the US each year.

How does Hugo compare to Intuitive Surgical's da Vinci system?

Da Vinci has held FDA clearance for general surgery procedures for years with a much larger installed base; Hugo is newly entering this segment after building its US presence in urology.